89Zr-panitumumab IV for Head-and-neck Squamous Cell Carcinoma

Phase-Based Progress Estimates
Stanford Cancer Institute, San Francisco, CA
Head-and-neck Squamous Cell Carcinoma+3 More
89Zr-panitumumab IV - Drug
All Sexes
What conditions do you have?

Study Summary

The purpose of this study is to determine the diagnostic utility of 89Zr-panitumumab to identify metastatic lesion(s) in subjects with head and neck squamous cell carcinoma (HNSCC).

Eligible Conditions

  • Head-and-neck Squamous Cell Carcinoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Head-and-neck Squamous Cell Carcinoma

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Up to 1 year

Up to 1 year
Sensitivity and Specificity 89Zr-panitumumab compared to standard of care 18F-FDG PET/CT imaging
Sensitivity and Specificity of 89Zr-panitumumab

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Head-and-neck Squamous Cell Carcinoma

Trial Design

2 Treatment Groups

panitumumab 30 mg
1 of 2
89Zr-panitumumab IV
1 of 2
Active Control
Experimental Treatment

60 Total Participants · 2 Treatment Groups

Primary Treatment: 89Zr-panitumumab IV · No Placebo Group · Phase 2

89Zr-panitumumab IV
Experimental Group · 1 Intervention: 89Zr-panitumumab IV · Intervention Types: Drug
panitumumab 30 mg
ActiveComparator Group · 1 Intervention: Panitumumab · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 1 year
Closest Location: Stanford Cancer Institute · San Francisco, CA
Photo of San Francisco  1Photo of San Francisco  2Photo of San Francisco  3
2017First Recorded Clinical Trial
1 TrialsResearching Head-and-neck Squamous Cell Carcinoma
44 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck.
You have a suspected metastatic lesion on FDG-PET/CT scan ≤ 30 days of Day 0.
You have a white blood cell count of at least 3000/mm3.
You have a PTT of 11.5 - 14.4 seconds.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.